These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37317850)

  • 1. Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA.
    Sinari S; Koska J; Hu Y; Furtado J; Jensen MK; Budoff MJ; Nedelkov D; McClelland RL; Billheimer D; Reaven P
    Arterioscler Thromb Vasc Biol; 2023 Aug; 43(8):1560-1571. PubMed ID: 37317850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein-CIII
    Naber A; Demus D; Slieker R; Nicolardi S; Beulens JWJ; Elders PJM; Lieverse AG; Sijbrands EJG; 't Hart LM; Wuhrer M; van Hoek M
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein-CIII O-Glycosylation Is Associated with Micro- and Macrovascular Complications of Type 2 Diabetes.
    Naber A; Demus D; Slieker RC; Nicolardi S; Beulens JWJ; Elders PJM; Lieverse AG; Sijbrands EJG; 't Hart LM; Wuhrer M; van Hoek M
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of apolipoprotein C-III proteoform composition with ankle-brachial index and peripheral artery disease in the Multi-Ethnic Study of Atherosclerosis (MESA).
    Koska J; Hansen S; Hu Y; Jensen MC; Billheimer D; Nedelkov D; Budoff MJ; Allison M; McClelland RL; Reaven PD
    Atherosclerosis; 2024 Aug; 395():117584. PubMed ID: 38823352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.
    Koska J; Yassine H; Trenchevska O; Sinari S; Schwenke DC; Yen FT; Billheimer D; Nelson RW; Nedelkov D; Reaven PD
    J Lipid Res; 2016 May; 57(5):894-905. PubMed ID: 26945091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not Just Arterial Damage: Increased Incidence of Venous Thromboembolic Events in Cardiovascular Patients With Elevated Plasma Levels of Apolipoprotein CIII.
    Olivieri O; Turcato G; Moruzzi S; Castagna A; Girelli D; Pizzolo F; Friso S; Sandri M; Bassi A; Martinelli N
    J Am Heart Assoc; 2019 Jan; 8(2):e010973. PubMed ID: 30646800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.
    Hiukka A; Fruchart-Najib J; Leinonen E; Hilden H; Fruchart JC; Taskinen MR
    Diabetologia; 2005 Jun; 48(6):1207-15. PubMed ID: 15864534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma proteoforms of apolipoproteins C-I and C-II are associated with plasma lipids in the Multi-Ethnic Study of Atherosclerosis.
    Koska J; Furtado J; Hu Y; Sinari S; Budoff MJ; Billheimer D; Nedelkov D; McClelland RL; Reaven PD
    J Lipid Res; 2022 Sep; 63(9):100263. PubMed ID: 35952903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Incidence of Ischemic Cerebrovascular Events in Cardiovascular Patients With Elevated Apolipoprotein CIII.
    Olivieri O; Cappellari M; Turcato G; Bonetti B; Girelli D; Pizzolo F; Friso S; Bassi A; Castagna A; Martinelli N
    Stroke; 2020 Jan; 51(1):61-68. PubMed ID: 31795904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides.
    Yassine HN; Trenchevska O; Ramrakhiani A; Parekh A; Koska J; Walker RW; Billheimer D; Reaven PD; Yen FT; Nelson RW; Goran MI; Nedelkov D
    PLoS One; 2015; 10(12):e0144138. PubMed ID: 26633899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
    Bajaj A; Xie D; Cedillo-Couvert E; Charleston J; Chen J; Deo R; Feldman HI; Go AS; He J; Horwitz E; Kallem R; Rahman M; Weir MR; Anderson AH; Rader DJ;
    Am J Kidney Dis; 2019 Jun; 73(6):827-836. PubMed ID: 30686529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Plasma Concentration of Apolipoprotein C-III Confers an Increased Risk of Cerebral Ischemic Events on Cardiovascular Patients Anticoagulated With Warfarin.
    Olivieri O; Turcato G; Cappellari M; Stefanoni F; Osti N; Pizzolo F; Friso S; Bassi A; Castagna A; Martinelli N
    Front Cardiovasc Med; 2021; 8():781383. PubMed ID: 35187103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism.
    Reyes-Soffer G; Sztalryd C; Horenstein RB; Holleran S; Matveyenko A; Thomas T; Nandakumar R; Ngai C; Karmally W; Ginsberg HN; Ramakrishnan R; Pollin TI
    Arterioscler Thromb Vasc Biol; 2019 Jan; 39(1):63-72. PubMed ID: 30580564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case-control study.
    Gerber Y; Goldbourt U; Segev S; Harats D
    Prev Med; 2003 Jul; 37(1):18-22. PubMed ID: 12799125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects.
    Rodríguez M; Rehues P; Iranzo V; Mora J; Balsells C; Guardiola M; Ribalta J
    J Proteomics; 2022 Jan; 251():104398. PubMed ID: 34688878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
    Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study.
    Roselli della Rovere G; Lapolla A; Sartore G; Rossetti C; Zambon S; Minicuci N; Crepaldi G; Fedele D; Manzato E
    Nutr Metab Cardiovasc Dis; 2003 Feb; 13(1):46-51. PubMed ID: 12772437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E.
    Clavey V; Lestavel-Delattre S; Copin C; Bard JM; Fruchart JC
    Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):963-71. PubMed ID: 7600129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of genotypes at the apolipoprotein AI-CIII-AIV, apolipoprotein B and lipoprotein lipase gene loci with coronary atherosclerosis and high density lipoprotein subclasses.
    Peacock RE; Hamsten A; Johansson J; Nilsson-Ehle P; Humphries SE
    Clin Genet; 1994 Oct; 46(4):273-82. PubMed ID: 7834891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Apo-CIII the new cardiovascular target? An analysis of its current clinical and dietetic therapies.
    de la Parra Soto LG; Gutiérrez-Uribe JA; Sharma A; Ramírez-Jiménez AK
    Nutr Metab Cardiovasc Dis; 2022 Feb; 32(2):295-308. PubMed ID: 34895805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.